Palvella Therapeutics (PVLA) Stock Price, News & Analysis

Company Overview

Palvella Therapeutics, Inc. (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes. Utilizing its integrated chemistry and biology capabilities, the company seeks to optimize drug candidates for favorable pharmacokinetics, safety, and efficacy profiles. Palvella has also established strategic partnerships with academic institutions and industry collaborators to accelerate its research and development efforts.

Headquartered in the United States, Palvella Therapeutics operates a dedicated research and development center where its multidisciplinary team of experts in immunology, medicinal chemistry, and clinical sciences drives program advancement. Since its inception, the company has demonstrated a commitment to expanding its pipeline through both internal discovery and external collaborations, with the ultimate goal of bringing new treatment options to patients suffering from debilitating inflammatory diseases.

Key Stats

• Today's Range: $149.98 to $154.30
• 50-Day Range: $124.15 to $157.77
• 52-Week Range: $53.30 to $161.38
• Volume: 163,345 shs
• Average Volume: 182,149 shs
• Market Capitalization: $2.16 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $209.14
• Consensus Rating: Buy

Palvella Therapeutics Stock Analysis - MarketRank™

Palvella Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 547th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Buy

Consensus Rating

Palvella Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 12 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Palvella Therapeutics has a consensus price target of $209.14, representing about 39.3% upside from its current price of $150.13.

Amount of Analyst Coverage

Palvella Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Palvella Therapeutics are expected to decrease in the coming year, from ($6.36) to ($8.01) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Palvella Therapeutics is -31.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Palvella Therapeutics is -31.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Palvella Therapeutics has a P/B Ratio of 63.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.21% of the float of Palvella Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Palvella Therapeutics has a short interest ratio ("days to cover") of 11.14, which indicates bearish sentiment.

Change versus previous month

Short interest in Palvella Therapeutics has recently increased by 6.59%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Palvella Therapeutics does not currently pay a dividend.

Dividend Growth

Palvella Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 1.17

News Sentiment

Palvella Therapeutics has a news sentiment score of 1.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Palvella Therapeutics this week, compared to 6 articles on an average week.

MarketBeat Follows

4 people have added Palvella Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Palvella Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,180,309.00 in company stock.

Percentage Held by Insiders

17.20% of the stock of Palvella Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

40.11% of the stock of Palvella Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 9/12/2026
• H.C. Wainwright 28th Annual Global Investment Conference: 9/15/2026
• Next Earnings (Estimated): 11/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PVLA
• Previous Symbol: NASDAQ:PVLA
• CIK: 1583648
• Web: www.pieris.com
• Phone: 857-246-8998
• Fax: 49-8161-141-1444
• Employees: N/A
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Palvella Therapeutics: $209.14
• High Price Target: $270.00
• Low Price Target: $133.00
• Potential Upside/Downside: +39.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.83)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$41.72 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -47.84%
• Return on Assets: -38.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 21.18
• Quick Ratio: 21.18

Sales & Book Value

• Annual Sales: $42.81 million
• Price / Sales: 50.53
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.36 per share
• Price / Book: 63.61

Miscellaneous

• Outstanding Shares: 14,410,000
• Free Float: 11,930,000
• Market Cap: $2.16 billion
• Optionable: N/A
• Beta: -0.25